- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07795164
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH (PERFORMA)
A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Shaheen Tomah, MD
- Telefoonnummer: 240-235-0145
- E-mail: performa@altimmune.com
Studie Locaties
-
-
Puerto Rico
-
San Juan, Puerto Rico, Puerto Rico, 00927
- Werving
- Altimmune Clinical Study Site
-
-
-
-
Alabama
-
Dothan, Alabama, Verenigde Staten, 36301
- Werving
- Altimmune Clinical Study Site
-
-
Arizona
-
Chandler, Arizona, Verenigde Staten, 85224
- Werving
- Altimmune Clinical Study Site
-
Tucson, Arizona, Verenigde Staten, 85712
- Werving
- Altimmune Clinical Study Site
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72205
- Werving
- Altimmune Clinical Study Site
-
North Little Rock, Arkansas, Verenigde Staten, 72117
- Werving
- Altimmune Clinical Study Site
-
-
California
-
Fountain Valley, California, Verenigde Staten, 92708
- Werving
- Altimmune Clinical Study Site
-
Fresno, California, Verenigde Staten, 93720
- Werving
- Altimmune Clinical Study Site
-
Gardena, California, Verenigde Staten, 90247
- Werving
- Altimmune Clinical Study Site
-
Huntington Park, California, Verenigde Staten, 90255
- Werving
- Altimmune Clinical Study Site
-
La Mesa, California, Verenigde Staten, 91942
- Werving
- Altimmune Clinical Study Site
-
Long Beach, California, Verenigde Staten, 90815
- Werving
- Altimmune Clinical Study Site
-
Orange, California, Verenigde Staten, 92866
- Werving
- Altimmune Clinical Study Site
-
Orange, California, Verenigde Staten, 92868
- Werving
- Altimmune Clinical Study Site
-
Poway, California, Verenigde Staten, 92064
- Werving
- Altimmune Clinical Study Site
-
Van Nuys, California, Verenigde Staten, 91405
- Werving
- Altimmune Clinical Study Site
-
-
Colorado
-
Englewood, Colorado, Verenigde Staten, 80113
- Werving
- Altimmune Clinical Study Site
-
-
Florida
-
Boca Raton, Florida, Verenigde Staten, 33434
- Werving
- Altimmune Clinical Study Site
-
Bradenton, Florida, Verenigde Staten, 34209
- Werving
- Altimmune Clinical Study Site
-
Miami, Florida, Verenigde Staten, 33173
- Werving
- Altimmune Clinical Study Site
-
Miami, Florida, Verenigde Staten, 33122
- Werving
- Altimmune Clinical Study Site
-
Miami Lakes, Florida, Verenigde Staten, 33016
- Werving
- Altimmune Clinical Study Site
-
Ocala, Florida, Verenigde Staten, 34471
- Werving
- Altimmune Clinical Study Site
-
Orlando, Florida, Verenigde Staten, 32803
- Werving
- Altimmune Clinical Study Site
-
Port Orange, Florida, Verenigde Staten, 32127
- Werving
- Altimmune Clinical Study Site
-
-
Georgia
-
Dalton, Georgia, Verenigde Staten, 30720
- Werving
- Altimmune Clinical Study Site
-
-
Indiana
-
South Bend, Indiana, Verenigde Staten, 46635
- Werving
- Altimmune Clinical Study Site
-
-
Louisiana
-
Bastrop, Louisiana, Verenigde Staten, 71220
- Werving
- Altimmune Clinical Study Site
-
Marrero, Louisiana, Verenigde Staten, 70072
- Werving
- Altimmune Clinical Study Site
-
Monroe, Louisiana, Verenigde Staten, 71201
- Werving
- Altimmune Clinical Study Site
-
-
Maryland
-
Laurel, Maryland, Verenigde Staten, 20708
- Werving
- Altimmune Clinical Study Site
-
-
Massachusetts
-
New Bedford, Massachusetts, Verenigde Staten, 02740
- Werving
- Altimmune Clinical Study Site
-
-
Missouri
-
Columbia, Missouri, Verenigde Staten, 65201
- Werving
- Altimmune Clinical Study Site
-
Kansas City, Missouri, Verenigde Staten, 64131
- Werving
- Altimmune Clinical Study Site
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87107
- Werving
- Altimmune Clinical Study Site
-
-
North Carolina
-
Fayetteville, North Carolina, Verenigde Staten, 28304
- Werving
- Altimmune Clinical Study Site
-
-
Ohio
-
Brooklyn, Ohio, Verenigde Staten, 44144
- Werving
- Altimmune Clinical Study Site
-
Springboro, Ohio, Verenigde Staten, 45066
- Werving
- Altimmune Clinical Study Site
-
Westlake, Ohio, Verenigde Staten, 44145
- Werving
- Altimmune Clinical Study Site
-
-
Rhode Island
-
East Greenwich, Rhode Island, Verenigde Staten, 02818
- Werving
- Altimmune Clinical Study Site
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78757
- Werving
- Altimmune Clinical Study Site
-
Bellaire, Texas, Verenigde Staten, 77401
- Werving
- Altimmune Clinical Study Site
-
Brownsville, Texas, Verenigde Staten, 78520
- Werving
- Altimmune Clinical Study Site
-
Corpus Christi, Texas, Verenigde Staten, 78404
- Werving
- Altimmune Clinical Study Site
-
Dallas, Texas, Verenigde Staten, 75230
- Werving
- Altimmune Clinical Study Site
-
Edinburg, Texas, Verenigde Staten, 78539
- Werving
- Altimmune Clinical Study Site
-
Farmers Branch, Texas, Verenigde Staten, 75234
- Werving
- Altimmune Clinical Study Site
-
Forney, Texas, Verenigde Staten, 75126
- Werving
- Altimmune Clinical Study Site
-
Fort Worth, Texas, Verenigde Staten, 76104
- Werving
- Altimmune Clinical Study Site
-
Georgetown, Texas, Verenigde Staten, 78626
- Werving
- Altimmune Clinical Study Site
-
Houston, Texas, Verenigde Staten, 77004
- Werving
- Altimmune Clinical Study Site
-
Houston, Texas, Verenigde Staten, 77079
- Werving
- Altimmune Clinical Study Site
-
Kingwood, Texas, Verenigde Staten, 77339
- Werving
- Altimmune Clinical Study Site
-
Pasadena, Texas, Verenigde Staten, 77505
- Werving
- Altimmune Clinical Study Site
-
San Antonio, Texas, Verenigde Staten, 78215
- Werving
- Altimmune Clinical Study Site
-
San Antonio, Texas, Verenigde Staten, 78209
- Werving
- Altimmune Clinical Study Site
-
San Antonio, Texas, Verenigde Staten, 78229
- Werving
- Altimmune Clinical Study Site
-
Sugar Land, Texas, Verenigde Staten, 77479
- Werving
- Altimmune Clinical Study Site
-
Waco, Texas, Verenigde Staten, 76710
- Werving
- Altimmune Clinical Study Site
-
-
Utah
-
Ogden, Utah, Verenigde Staten, 84405
- Werving
- Altimmune Clinical Study Site
-
West Jordan, Utah, Verenigde Staten, 84088
- Werving
- Altimmune Clinical Study Site
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Werving
- Altimmune Clinical Study Site
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
All subjects:
- No significant changes in body weight (±5%) and not participating in a structured weight loss program for the 3 months prior to screening (or since the historical biopsy, if applicable)
- Body mass index (BMI) ≥ 25.0 kg/m2; if Asian, BMI ≥ 23.0 kg/m2
- Type 2 diabetes (T2D) or at least 2 components of metabolic syndrome
- Subject agrees to have liver biopsy(ies) as required per protocol
Cohort 1 - Histologic diagnosis of F2/F3 MASH based on liver biopsy during screening or historical biopsy within 6 months before screening
Cohort 2 - Presumed F2/F3 MASH based on noninvasive testing
Exclusion Criteria:
- Cirrhosis (F4); portal hypertension or hepatic decompensation; acute or chronic liver disease other than MASH; liver function tests (ALT, AST; alkaline phosphatase; total bilirubin; INR; and platelet count) outside of acceptable ranges; positive HBsAg; active hepatitis C
- Uncontrolled T2D or clinically significant persistent hyperglycemia
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
|
Placebo SC Injection |
|
Experimenteel: Pemvidutide 2,4 mg
|
Pemvidutide SC Injection |
|
Experimenteel: Pemvidutide 1.8 mg
|
Pemvidutide SC Injection |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Clinical Outcome Event
Tijdsspanne: Baseline through end of study (approximately Month 60)
|
Time to first occurrence of any of the following events through the end of the study: Histologic progression to cirrhosis (F4) on liver biopsy; Liver related events; Liver transplantation; or Death due to any cause |
Baseline through end of study (approximately Month 60)
|
|
Histological Response: MASH resolution
Tijdsspanne: Baseline through Week 52
|
Proportion of subjects achieving MASH resolution (according to NASH Clinical Research Network [CRN] classification) without worsening of fibrosis |
Baseline through Week 52
|
|
Histological Response: Fibrosis improvement
Tijdsspanne: Baseline through Week 52
|
Proportion of subjects achieving ≥ 1 stage improvement in liver fibrosis according to the NASH CRN fibrosis staging system without worsening of MASH |
Baseline through Week 52
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Histologic Response: Proportion of subjects achieving both MASH resolution (according to NASH CRN classification) without worsening of fibrosis and ≥ 1 stage improvement in liver fibrosis without worsening of MASH
Tijdsspanne: Baseline through Week 52
|
Baseline through Week 52
|
|
HistoIndex qFibrosis: Proportion of subjects with at least a 1 stage improvement in qFibrosis
Tijdsspanne: Baseline through Week 52
|
Baseline through Week 52
|
|
Anthropometric parameters: Relative (%) change from baseline in body weight (kg)
Tijdsspanne: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in body mass index (BMI; kg/m2)
Tijdsspanne: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Anthropometric parameters: Relative (%) change from baseline in waist circumference (cm)
Tijdsspanne: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in alanine aminotransferase (ALT; U/L)
Tijdsspanne: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Absolute change from baseline in enhanced liver fibrosis (ELF) score
Tijdsspanne: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
Noninvasive Tests of MASH Inflammatory and Fibrotic Activity: Relative (%) change from baseline in vibration controlled transient elastography (VCTE; kPa) by Fibroscan
Tijdsspanne: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in core symptoms of MASH on the NASH-CHECK questionnaire.
Tijdsspanne: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Short-form 36 (SF-36) summary scores.
Tijdsspanne: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
|
HRQoL: Change from baseline in Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis (CLDQ-NASH) domain scores.
Tijdsspanne: Baseline through End of Study (approximately Month 60)
|
Baseline through End of Study (approximately Month 60)
|
Medewerkers en onderzoekers
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- ALT-801-301
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .